These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37346975)

  • 21. Clinical, biochemical and genetic characteristics of MOGS-CDG: a rare congenital disorder of glycosylation.
    Shimada S; Ng BG; White AL; Nickander KK; Turgeon C; Liedtke KL; Lam CT; Font-Montgomery E; Lourenco CM; He M; Peck DS; Umana LA; Uhles CL; Haynes D; Wheeler PG; Bamshad MJ; Nickerson DA; Cushing T; Gates R; Gomez-Ospina N; Byers HM; ; Scalco FB; Martinez NN; Sachdev R; Smith L; Poduri A; Malone S; Harris RV; Scheffer IE; Rosenzweig SD; Adams DR; Gahl WA; Malicdan MCV; Raymond KM; Freeze HH; Wolfe LA
    J Med Genet; 2022 Jul; ():. PubMed ID: 35790351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of Cas9 by viral proteins Tat and Rev for HIV-1 inactivation.
    Vergara-Mendoza M; Gomez-Quiroz LE; Miranda-Labra RU; Fuentes-Romero LL; Romero-Rodríguez DP; González-Ruiz J; Hernández-Rizo S; Viveros-Rogel M
    Antiviral Res; 2020 Aug; 180():104856. PubMed ID: 32579898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.
    Saayman SM; Lazar DC; Scott TA; Hart JR; Takahashi M; Burnett JC; Planelles V; Morris KV; Weinberg MS
    Mol Ther; 2016 Mar; 24(3):488-98. PubMed ID: 26581162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updated clinical and glycomic features of mannosyl-oligosaccharide glucosidase deficiency: Two case reports.
    Abuduxikuer K; Wang L; Zou L; Cao CY; Yu L; Guo HM; Liang XM; Wang JS; Chen L
    World J Clin Cases; 2022 Jul; 10(21):7397-7408. PubMed ID: 36158009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiplexed
    Ophinni Y; Miki S; Hayashi Y; Kameoka M
    Viruses; 2020 Oct; 12(11):. PubMed ID: 33126728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-κB Activity.
    Peters RJ; Stevenson M
    J Virol; 2022 Jun; 96(12):e0048422. PubMed ID: 35604217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR-Cas9 screen of E3 ubiquitin ligases identifies TRAF2 and UHRF1 as regulators of HIV latency in primary human T cells.
    Rathore U; Haas P; Easwar Kumar V; Hiatt J; Haas KM; Bouhaddou M; Swaney DL; Stevenson E; Zuliani-Alvarez L; McGregor MJ; Turner-Groth A; Ochieng' Olwal C; Bediako Y; Braberg H; Soucheray M; Ott M; Eckhardt M; Hultquist JF; Marson A; Kaake RM; Krogan NJ
    mBio; 2024 Apr; 15(4):e0222223. PubMed ID: 38411080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile?
    De Silva Feelixge HS; Stone D; Roychoudhury P; Aubert M; Jerome KR
    ACS Infect Dis; 2018 Jun; 4(6):871-880. PubMed ID: 29522311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiplexed Simian Immunodeficiency Virus-Specific Paired RNA-Guided Cas9 Nickases Inactivate Proviral DNA.
    Smith LM; Ladner JT; Hodara VL; Parodi LM; Harris RA; Callery JE; Lai Z; Zou Y; Raveedran M; Rogers J; Giavedoni LD
    J Virol; 2021 Nov; 95(23):e0088221. PubMed ID: 34549979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections.
    Chang J; Block TM; Guo JT
    Antivir Ther; 2015; 20(3):257-9. PubMed ID: 25318123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation.
    Byrne G; O'Rourke SM; Alexander DL; Yu B; Doran RC; Wright M; Chen Q; Azadi P; Berman PW
    PLoS Biol; 2018 Aug; 16(8):e2005817. PubMed ID: 30157178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism-related MOGS Gene is Dysregulated After Peripheral Nerve Injury and Negatively Regulates Schwann Cell Plasticity.
    Zhang Y; Yang M; Shen Y; Yi S; Wang X
    J Mol Neurosci; 2022 Jun; 72(6):1402-1412. PubMed ID: 35575968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection.
    Maslennikova A; Mazurov D
    Front Cell Infect Microbiol; 2022; 12():880030. PubMed ID: 35694537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
    Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
    BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic application of CRISPR/Cas9 technologies for HIV.
    Saayman S; Ali SA; Morris KV; Weinberg MS
    Expert Opin Biol Ther; 2015 Jun; 15(6):819-30. PubMed ID: 25865334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy.
    Xiao Q; Guo D; Chen S
    Front Cell Infect Microbiol; 2019; 9():69. PubMed ID: 30968001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycosylation, hypogammaglobulinemia, and resistance to viral infections.
    Sadat MA; Moir S; Chun TW; Lusso P; Kaplan G; Wolfe L; Memoli MJ; He M; Vega H; Kim LJY; Huang Y; Hussein N; Nievas E; Mitchell R; Garofalo M; Louie A; Ireland DC; Grunes C; Cimbro R; Patel V; Holzapfel G; Salahuddin D; Bristol T; Adams D; Marciano BE; Hegde M; Li Y; Calvo KR; Stoddard J; Justement JS; Jacques J; Priel DAL; Murray D; Sun P; Kuhns DB; Boerkoel CF; Chiorini JA; Di Pasquale G; Verthelyi D; Rosenzweig SD
    N Engl J Med; 2014 Apr; 370(17):1615-1625. PubMed ID: 24716661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivation of Latent HIV-1 Proviral DNA Using Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Treatment and the Assessment of Off-Target Effects.
    Xu Y; Peng X; Zheng Y; Jin C; Lu X; Han D; Fu H; Chen C; Wu N
    Front Microbiol; 2021; 12():629153. PubMed ID: 34122355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
    Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineering T-Cell Resistance to HIV-1 Infection via Knock-In of Peptides from the Heptad Repeat 2 Domain of gp41.
    Maslennikova A; Kruglova N; Kalinichenko S; Komkov D; Shepelev M; Golubev D; Siniavin A; Vzorov A; Filatov A; Mazurov D
    mBio; 2022 Feb; 13(1):e0358921. PubMed ID: 35073736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.